Gemcitabine
- PDF / 141,734 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 89 Downloads / 180 Views
1
S
Thrombotic microangiopathy: case report A 48-year-old woman developed thrombotic microangiopathy during treatment with gemcitabine. The woman underwent resection of a malignant thymoma with capsular invasion and post-operative scanning revealed residual tissue at the resection site. She received mediastinal radiotherapy and, 1 month later, started receiving IV gemcitabine 1000 mg/m2 biweekly. Two days after her second infusion, she developed symmetrical purpura on her trunk, forearms and proximal lower limbs. Laboratory tests revealed thrombocytopenia (130 000/mm3), decreased haemoglobin levels (12.0 g/dL) and a slight increase in creatinine levels (1.0 mg/dL). Within 5 days, her rash had resolved. Following normalisation of her laboratory parameters, 18 days after the second gemcitabine infusion, the woman received her third infusion. A few hours later, her rash recurred in greater extent and intensity covering almost her whole body except her face. She had a temperature of 38.5°C and new-onset hypertension (160/90mm Hg). Laboratory tests revealed severe thrombocytopenia (50 000 /mm3), a decreased haemoglobin level (11.5 mg/dL) [sic] and a creatinine level of 1.6 mg/dL. Peripheral blood smear revealed 1+ schistocytes. She had slightly increased LDH levels and a decreased serum haptoglobin level. Findings indicated thrombotic microangiopathy. She received high-dose corticosteroids and antihypertensives. Her rash persisted for 16 days and her platelet count normalised. However, her renal function did not return to baseline. Gemcitabine was not reinitiated. Saif MW, et al. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opinion on Drug Safety 8: 257-60, No. 3, May 2009 803010005 USA
0114-9954/10/1297-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 17 Apr 2010 No. 1297
Data Loading...
